Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study by Petter Tinghög et al.
Tinghög et al. BMC Neurology 2014, 14:117
http://www.biomedcentral.com/1471-2377/14/117RESEARCH ARTICLE Open AccessCo-morbidities increase the risk of disability
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nationwide cohort study
Petter Tinghög1*, Charlotte Björkenstam1, John Carstensen2, Catarina Jansson1, Anna Glaser1, Jan Hillert1
and Kristina Alexanderson1Abstract
Background: Multiple sclerosis (MS) is a chronic and often disabling disease. In 2005, 62% of the MS patients in
Sweden aged 16–65 years were on disability pension. The objective of this study is to investigate whether the
presence of common co-morbidities increase MS patients’ risk for disability pension.
Methods: This population-based cohort study included 4 519 MS patients and 4 972 174 non-MS patients who in
2005 were aged 17–64 years, lived in Sweden, and were not on disability pension. Patients with MS were identified
in the nationwide in- and outpatient registers, while four different registers were used to construct three sets of
measures of musculoskeletal, mental, and cardiovascular disorders. Time-dependent proportional hazard models
with a five-year follow up were performed, adjusting for socio-demographic factors.
Results: All studied disorders were elevated among MS patients, regardless of type of measure used. MS patients
with mental disorders had a higher risk for disability pension than MS patients with no such co-morbidities. Moreover,
mental disorders had a synergistic influence on MS patients’ risk for disability pension. These findings were also
confirmed when conducting sensitivity analyses. Musculoskeletal disorders appeared to increase MS patients’ risk for
disability pension. The results with regard to musculoskeletal disorders’ synergistic influence on disability pension
were however inconclusive. Cardiovascular co-morbidity had no significant influence on MS-patients’ risk for disability
pension.
Conclusions: Co-morbidities, especially mental disorders, significantly contribute to MS patients’ risk of disability
pension, a finding of relevance for MS management and treatment.
Keywords: Multiple sclerosis, Co-morbidity, Disability pension, Sick leave, Synergistic effects, Insurance medicineBackground
Multiple sclerosis (MS) is an often progressive neurological
disorder that may lead to substantial disability [1-3]. Some
MS patients quickly experience permanent work incapacity
while others maintain a high level of work capacity
for several years [4,5]. Co-morbidity has been suggested as
a key factor for understanding heterogeneity of the MS
progression [6].
Research on how MS-patients are affected by co-
morbidities has so far focused on other outcomes than* Correspondence: petter.tinghog@ki.se
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health-related quality of life, [8] and physical functioning
[9]. It has been reported that MS patients with vascular
disorders are more likely to suffer from ambulatory
disability, [7] that MS patients with musculoskeletal
disorders have a more rapid decline of motor functions,
[10] and that mental disorders among MS patients are
linked to decreased physical functioning [11] and increased
perceived disability [12]. No population-based study
with a comparison group of non-MS patients has, to
our knowledge, been conducted to determine if MS
in combination with other disorders has a synergistic
influence on a disability outcome. We have chosen DP as
an outcome as it also involves the social consequencesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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incapacity.
This study aimed at analyzing; 1) the presence of
musculoskeletal, cardiovascular, and mental disorders
in MS patients and in the general population of
working ages; 2) if musculoskeletal, cardiovascular,
and mental co-morbidity increase the risk of DP among
MS patients; and 3) if these three types of disorders act
synergistically on MS patients’ risk for DP.
This study shows that co-morbidities, especially
mental disorders, significantly contribute to MS patients’
risk of disability pension.
Methods
A population-based nationwide prospective cohort
study with a five-year follow-up period (2006–2010)
was conducted. All 5 709 769 people aged 17–64 who
lived in Sweden in 2005 not on DP, old-age pension or
with missing values on any of the covariates were
followed, including all 4 519 MS patients and all those
who did not receive a MS diagnosis during follow-up
(N = 4 972 174), here called non-MS patients (Table 1).
However, some analyses are based on all individuals
with complete data and no MS-diagnosis during
follow-up in order to evaluate how individuals on DP
were selected with regard to socio-demographics and
co-morbidities. Hence, these analyses include also those
that at baseline were on early old-age pension or DP.
Linkage and data sources
By using the Personal Identity Number (a unique
ten-digit number assigned to all Swedish residents),
data from the following five nationwide registers
were linked for each of the included individuals: 1)
Statistics Sweden’s Longitudinal Integration Database
for Health Insurance and Labor Market Studies
(LISA) regarding data on socio-demographics and
migration; 2) Social Insurance Agency’s database Micro
Data for Analysis of the Social Insurance (MiDAS)
regarding data on disability pension and diagnosis-specific
sick-leave; 3) National Board of Health and Welfare’s
databases National Patient Register (PAR), 4) Swedish
Prescribed Drug Register (PDR), and 5) the Causes of
Death Register from which data about diagnosis-specific
in- and specialized outpatient care, prescribed drugs, and
year of death, respectively, were obtained. All five registers
are longitudinal, but differ with regard to when they were
instigated. Important to mention in relation to this study
is that nationwide specialized outpatient data only is
available from 2001 and onwards, that reliable data on
sick-leave diagnoses is available from 2004, and that the
PDR register started 1 July 2005.
The study was approved by the Regional Ethical Review
Board in Stockholm, Sweden.Outcome variable
In Sweden, all adult residents with a disease or injury
that has led to permanent work incapacity are entitled
to disability pension. Disability pension covers up to 64%
of the lost income. The customary age for old-age pension
is 65 years, but may be taken earlier. Also, all people above
the age of 16 with income from work or unemployment
benefits can be entitled to sickness benefits if a disease or
injury has led to work incapacity.
Exposure variable
The MS patients were identified using the nationwide
PAR; that is, those who had at least one hospitalization or
outpatient specialist visit due to MS as a main or secondary
diagnosis during 2000–2005, classified according to the
International Statistical Classification of Diseases and
Related Health problems ICD-10 [13]; G35.
Time-dependent covariates
Separate time-dependent dummy variables were con-
structed for musculoskeletal, cardiovascular, and mental
disorders. Year-specific data for these disorders were
retrieved from the PDR, MiDAS, and PAR, respectively.
The first year the disorder was observed and the years
following were coded as 1, while the preceding years
were coded as 0. Individuals without the respective
disorder were consistently coded as 0. To circumvent
some of the potential drawback inherited with using
register data to identify individuals with these three
classes of disorders [14], three different types of measures
were constructed.
In the first, and most inclusive, measure, i.e. model 1,
individuals were classified as having musculoskeletal
disorder at baseline if they had been hospitalized or
received specialized outpatient care between 2000 and
2005 with a musculoskeletal disorder (ICD-10: M00-M99),
or had been sickness absent due to musculoskeletal
diagnoses (ICD-10: M00-M99) in 2004 or 2005. Also,
from the PDR we used prescriptions for dispensed
drugs licensed for musculoskeletal disorders (Anatomical
Therapeutical Chemical Classification (ATC)-codes:
M01-M09) in 2005. Similarly, individuals were classified
as suffering from cardiovascular and mental disorders in
the same manner, using the following ATC and diagnostic
codes: cardiovascular disorders ATC: C01-C10; ICD-10:
I00-I99 and mental disorders ATC: N05-N06; ICD-10:
F00-F99.
As we were concerned about overestimation and that
differential misclassification may bias the estimates
obtained when applying the above described measures –
in particular relevant for PDR data since no information
on indication is included in this register that may make it
a less specific proxy for diagnosis – two additional and
more conservative measures were constructed. In the first
Table 1 Baseline descriptives (2005) in percentages and incidence rates (IRs) for DP per 100 000 person-years
(2006–2010) among MS patients and the general population, respectively
MS patients General population
All (n = 10 750) At risk for DP (n = 4 519) All (n = 5 553 120) At risk for DP (n = 4 972 174)
% % Person-years at risk IRs % % Person-years at risk IRs
Gender
Women 70.8 67.8 12 744 69.1 49.2 48.1 11 324 670 7.0
Men 29.2 32.2 6140 61.6 50.8 51.9 12 271 042 4.6
Age (mean years) 47.0 41.2 40.1 39.6
Age-groups
17-24 2.3 4.8 949 40.0 15.1 16.6 4 033 844 2.7
25-34 13.2 24.5 4 977 41.4 20.2 21.9 5 284 065 2.3
35-44 24.0 32.3 6 235 64.7 22.6 23.6 5 719 389 4.5
45-54 29.6 25.9 4 727 88.6 20.7 20.2 4 874 419 7.6
55-64 30.8 12.4 1 996 96.2 21.4 17.7 3 683 995 13.5
Living with partner
No 45.1 42.1 8 018 60.6 50.3 50.1 11 733 753 5.7
Yes 54.9 57.9 10 866 71.0 49.7 49.9 11 861 959 5.6
Educational level
Compulsory School (≤9 years) 17.1 9.6 1 656 92.4 20.2 18.5 4 258 677 9.2
High School (10–12 years) 49.1 45.3 8 408 75.5 47.8 47.8 11 339 322 5.9
University (≥13 years) 33.7 45.1 8 820 53.3 32.0 33.7 7 997 713 3.7
Country of birth
Sweden 90.9 90.7 17 143 67.4 85.9 86.4 20 482 499 5.3
Other Nordic countries 2.9 2.4 420 81.0 3.1 2.8 621 577 10.0
EU 25 2.0 1.8 350 37.1 2.1 2.0 438 850 7.6
Other world 4.3 5.2 971 57.7 8.9 8.8 2 052 786 8.3
Type of living area
Larger cities 36.8 41.6 8 137 50.8 37.1 37.5 8 854 806 4.7
Medium-sized municipalities 35.4 35.5 6 642 70.6 35.4 36.0 8 505 141 6.1
Smaller municipalities 27.8 22.9 4 105 91.6 27.5 26.5 6 235 765 6.7
Geographic region
Stockholm County 22.3 26.8 5 174 46.2 21.5 21.8 3 951 156 4.6
East Middle Sweden 16.8 16.8 3 126 73.3 16.8 16.7 2 053 102 5.8
Småland and Islands 8.2 7.7 1 389 82.1 8.6 8.7 3 421 054 6.5
South Sweden 13.9 14.9 2 819 69.9 14.5 14.6 4 720 280 6.4
West Sweden 20.3 18.4 3 546 61.2 20.0 20.0 2 056 790 5.5
North Middle Sweden 8.5 7.1 1 267 90.0 8.9 8.7 934 219 5.8
Middle Norrland 3.9 3.4 607 100.5 4.0 4.0 1 302 967 7.6
Upper Norrland 6.0 5.3 956 91.0 5.6 5.5 3 951 156 7.0
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on the sole basis of the sick leave and the in- and out-
patient diagnoses, i.e., PAR and MiDAS. The second type
of alternative measures, i.e. model 3, were based on all
four registers as described above (i.e. in and outpatient
PAR, MiDAS and PDR), with the exception that drugs
belonging to ATC groups hypnotics and sedatives (N05C),centrally acting sympathomimetics (N06BA), anesthetics
(M01), and muscle relaxants (M03) were excluded, as
drugs of these kinds may be prescribed to treat MS
symptoms.
Cohabiting status was also constructed as a time-
dependent variable, but in this case individuals were only
classified in reference to the preceding year.
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Those living in Sweden all of 2005 were identified
through LISA and the following fixed covariates, i.e. at
baseline, were retrieved from LISA: age-groups (17–24,
25–34, 35–44, 45–54, 55–64); educational level [com-
pulsory school (≤9 years), high school (10–12 years),
university (≥13 years)]; country of birth (Sweden, other
Nordic countries, EU 25 or other countries); type of
living area [based on the H-region classification scheme
[15] into the following 3 categories: larger cities (H1-H2),
medium-sized municipalities (H3-H4), or smaller munici-
palities (H5-H6)]; and geographic region [in 8 categories;
Stockholm County, South Sweden, East Middle Sweden,
North Middle Sweden, Middle Norrland, Småland and
Islands, West Sweden, or Upper Norrland in accordance
with Eurostat’s Nomenclature of Territorial Units for
Statistics, (NUTS) classification (level 2)].
Statistical analyses
The cohort was followed from 2006 through 2010 or the
year the individual turned 65, emigrated, died, or received
DP, whichever came first. Hazard ratios (HRs) with
95% confidence intervals (CIs) were estimated by
time-dependent proportional hazards model.
First, descriptive analyses were performed to explore
the distribution of the baseline covariates among MS
patients and in the general population, respectively.
The absolute risks for DP by baseline characteristics
were calculated for MS patients and the general
population and presented as incidence rates (IRs) per
100 000 person-years.
Second, 5-year prevalence estimates, based on the
three specified types of measures, of musculoskeletal,
cardiovascular, and mental disorders were computed for
MS patients and the general population. The MS patients’
and the general population’s 5-year prevalence estimates
were compared in adjusted logistic regression analyses.
Separate analyses were conducted for those at risk for DP
and all individuals, i.e. including also those on early
old-age pension or DP. Incidence rates for DP (IRs)
per 100 000 person-years were provided for the MS
patients and the general population, respectively.
Third, models based on the three specified types of
measures of disorders were tested to establish whether
the studied co-morbid conditions influenced the MS
patients’ risk for DP. To illustrate effect-modifications
also HRs with 95% CIs were calculated for the general
population. Effect-modifications were evaluated using
Wald ×2 tests.
Fourth, Rothman’s synergy index (SI) and attributable
proportion due to interaction (AP) were calculated [16].
These statistics were obtained with 95% CIs, following
Andersson et al’s recommendations [17]. A SI above 1
indicates a synergistic effect and a SI lower than 1indicates an antagonistic synergistic effect. Models based
on the three pre-specified types of proxy measures were
tested separately.
Results
Table 1 shows that MS patients have a different
socio-demographic profile than the general population. The
MS patients were more often women, cohabiting, university
educated, and born in Sweden. It was also noticeable that
the socio-demographic differences between MS patients
and the general population became more pronounced
when comparing only those at risk for DP. Furthermore,
older age, lower educational level, living in a small
municipality or in the northern part of Sweden seemed to
be predictors of DP in the MS population. In the general
population, similar trends were observed, though the
absolute DP risks were overall much lower.
Table 2 reveals that the 5-year prevalence estimates of
musculoskeletal, cardiovascular, and mental disorders
were higher in the MS population than in the general
population. This was evident in both the analyses based
on the individuals at risk for DP and in analyses including
all individuals (i.e. also those on early old-age pension or
DP). In particular, it was shown that mental disorders
were elevated among MS patients. All the results appeared
robust, as MS patient have a significantly higher risk
for all the respective disorders, regardless of the type
of measure used. In general, however, the analyses based
on the most inclusive of measure (model 1) rendered
somewhat stronger associations.
According to model 1 (Table 3), MS patients with mus-
culoskeletal or mental disorders had a higher risk for DP;
HR 1.49 (1.33-1.67) and 2.44 (1.18-2.74), respectively.
Cardiovascular disorders, however, did not appear to
influence MS patients’ HR for DP; HR 1.02 (0.90-1.16).
The alternative models showed similar trends; albeit
musculoskeletal disorders’ influence on the MS patients’
HR for DP were weaker and non-significant in the
model in which anesthetics (M01) and muscle relaxants
(M03) were excluded from the case ascription definition
(Model 3). Moreover, musculoskeletal, cardiovascular, and
mental disorders were stronger risk factors, in relative
terms, for DP in the general population than among MS
patients. This is hardly surprising, given that DP overall is
much more prevalent among MS patients than in the
general population.
Table 4, in which the synergistic effects from model 1
are presented, shows that having mental disorders in
combination with MS had a much greater influence on the
HR for DP than those two disorders had individually when
added up, i.e. AP 48.0% (44.1-51.8); SI 1.98 (1.84-2.14). This
finding was confirmed in the model where hypnotics and
sedatives (N05C) and centrally acting sympathomimetics
(N06BA) drugs were excluded, and when analyses solely
Table 2 Five year prevalence estimates for different measures (2000–2005) for musculoskeletal, cardiovascular and
mental disorders among MS patients and the general population, with incidence rates (IRs) for DP per 100 000
person-years and adjusted odds ratios (ORs) with 95% confidence intervals (CIs)




(at risk for DP)d
All
(n = 10 791)
At risk for DP
(n = 4 519)
All
(n = 5 618 191)
At risk for DP
(n = 4 972 174)
Model 1b % % IRs % % IRs Adj ORs CI 95% Adj ORs CI 95%
Musculoskeletal disorders
Yes 43.5 33.8 88.2 22.1 19.7 15.1 2.21 (2.11-2.28) 1.91 (1.79-2.03)
No 56.4 3.5
Cardiovascular disorders
Yes 24.8 15.4 90.5 14.6 12.4 15.7 1.42 (1.36-1.49) 1.34 (1.23-1.46)
No 62.6 4.4
Mental disorders




Yes 22.0 18.7 81.9 15.6 13.6 17.8 1.25 (1.19-1.31) 1.37 (1.27-1.48)
No 63.3 3.9
Cardiovascular disorders
Yes 12.2 8.0 85.1 6.9 5.5 19.6 1.47 (1.39-1.57) 1.55 (1.39-1.67)
No 65.1 5.0
Mental disorders




(exl. ATC: M01, M03)




Yes 35.8 22.1 110.1 13.9 10.7 26.0 2.80 (2.69-2.91) 2.03 (1.89-2.18)
No 55.8 3.4
aPrevalence estimates are based on sick-leave (MiDAS) and on in- and out-patient ICD-10 diagnoses (PAR); M00-M99, I00-I99 and F00-F99.
bPrevalence estimates are based on sick-leave (MiDAS) and on in- and out-patient ICD-10 diagnoses (PAR); M00-M99, I00-I99 and F00-F99, and the following
ATC-codes (PDR); M01-M09. C01-C10 and N05-N06.
cPrevalence estimates are based on the same criteria as the model 1, except that hypnotics and sedatives (ATC: N05C), centrally acting sympathomimetics (N06BA)
anesthetics (M01), and muscle relaxants (M03) are excluded from the case definition.
dAll analyses are adjusted for gender and age-groups. In the models the general population is coded as the reference category, i.e. ORs >1 indicate that
MS-patients are more likely to have a particular type of disorder.
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i.e. model 2 and 3 (data not shown). Musculoskeletal
disorders were shown to have a synergistic influence
on MS patients’ risk for DP, when the model 1 (the
most inclusive model) was applied, i.e. AP 29.6%
(22.3-34.9); SI 1.44 (1.33-1.56). This synergy effect
was, however, not found when the more conservative
case ascription methods were used, i.e. model 2 and 3(data not shown). These additional analyses thus cast
serious doubt with regard to the presence of a synergistic
effect between MS and musculoskeletal disorders in
relation to DP.
Age- (16–44 and 45–64 years) and gender-stratified
analyses were conducted to evaluate the fit of the
models (data not shown). The estimates from these
analyses (based on model 1) concerning the influence
Table 3 The influence of different measures for musculoskeletal, cardiovascular, and mental disorders on DP among
MS patients and the general population during follow-up 2006–2010 estimated as hazard ratios (HRs) with 95%
confidence intervals (CI)
Modelsa MS patients HRs (95% CI) General population HRs (95% CI) Effect modifications Wald X2 (p-values)
Model 1b
Musculoskeletal disorders 1.49 (1.33-1.67) 2.51 (2.48-2.54) 80.44 (<0.01)
Cardiovascular disorders 1.02 (0.90-1.16) 1.70 (1.68-1.72) 60.96 (<0.01)
Mental disorders 2.44 (1.18-2.74) 6.97 (6.88-7.05) 318.93 (<0.01)
Model 2c
Musculoskeletal disorders 1.16 (1.03-1.32) 3.34 (3.30-3.71) 274.50 (<0.01)
Cardiovascular disorders 1.09 (0.92-1.29) 2.16 (2.14-2.19) 64.87 (<0.01)
Mental disorders 1.56 (1.35-1.80) 6.15 (6.08-6.22) 341.33 (<0.01)
Model 3d
Musculoskeletal disorders 1.10 (0.98-1.53) 3.05 (3.02-3.10) 260.53 (<0.01)
Cardiovascular disorders 1.05 (0.92-1.19) 1.73 (1.71-1.75) 59.40 (<0.01)
Mental disorders 2.27 (2.03-2.53) 7.02 (6.94-7.10) 388.42 (<0.01)
aAll models are adjusted for gender, age, educational level, country of birth, type of living area, geographic region, and cohabiting status. Cohabiting status,
cardiovascular, musculoskeletal, and mental disorder are modeled as time-dependent covariates. Not having the specific disorder is the reference category.
bCardiovascular, musculoskeletal, and mental disorder variables are based sick-leave (MiDAS) and in and out-patient ICD-10 diagnoses (PAR); M00-M99, I00-I99 and
F00-F99, and the following ATC-codes (PDR); M01-M09, C01-C10 & N05-N06.
cCardiovascular, musculoskeletal, and mental disorder variables are based on sick-leave (MiDAS) and in- and out-patient ICD-10 diagnoses (PAR); M00-M99, I00-I99
and F00-F99.
dCardiovascular, musculoskeletal, and mental disorder variables are based on the same criteria as model 1, except that the drugs hypnotics and sedatives
(ATC: N05C), centrally acting sympathomimetics (N06BA) anesthetics (M01), and muscle relaxants (M03) have been excluded from the case definition.
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groups. However, worth mentioning is that cardiovascular
disorders were associated with a higher HR for DP among
the younger MS patients, i.e. HR 1.38 (1.13-1.69).
Discussion
This prospective and population-based register study is, as
far as we know, the first dealing with how co-morbidityTable 4 Musculoskeletal, cardiovascular, and mental disorder
presented as hazard ratios (HRs), attributable proportion due
Models
Model 1 No musculoskeletal disorder and no MS
Musculoskeletal disorder (only)
MS (only) 16
Musculoskeletal disorder and MS 27
Model 1 No cardiovascular disorder and no MS
Cardiovascular disorder (only)
MS (only) 15
Cardiovascular disorders and MS 17
Model 1 No mental disorder and no MS
Mental disorder (only)
MS (only)
Mental disorder and MS 30
aThe cardiovascular, musculoskeletal, and mental disorder variables are based on si
I00-I99 and F00-F99, and the following ATC-codes (PDR); M01-M09, C01-C10 and N0
time-dependent covariates. The models are also adjusted for gender, age, educatio
All estimates are supplemented with 95% confidence intervals (95% CI).influences MS patients’ risk for DP. As expected, MS
patients with musculoskeletal and mental co-morbidity
had a higher risk for DP, but contrary to our expectation,
cardiovascular disorders did not increase MS patients’
risk for DP compared to MS patients without such
co-morbidity. Our results also showed that musculoskeletal,
cardiovascular, and mental disorders were more common
among MS patients of working ages but were, in a relatives’ synergistic influence on DP in a five-year follow up,
to interaction (AP), and synergy index (SI)a












.99 (28.56-33.64) 48.0 (44.1-51.8) 1.98 (1.84-2.14)
ck-leave (MiDAS) and in- and out-patient ICD-10 diagnoses (PAR); M00-M99,
5-N06. Exposure variables and cohabiting status are modeled as
nal level, country of birth, type of living area, and geographic region.
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than in the MS population. Furthermore, mental disorders
had a synergistic influence on MS patients’ risk for DP. The
results regarding musculoskeletal disorders synergistic
influence on DP were inconclusive.
The finding that musculoskeletal and mental disorders
increased MS patients’ risk for DP is in accordance with
previous research where different disability measures
have been used [10-12]. It was, however, unexpected that
cardiovascular disorders did not predict DP among MS
patients. This may be interpreted as that this specific
co-morbid condition is negligible in the context of
MS and work incapacity, as MS in itself is a severe
and disabling disorder. It may also be a result of that a
cardiovascular disorder often are attained after the age of
50, when many MS patients already have experienced a
reduced work capacity and been granted disability pension.
In contrast to our results, a large US cohort study
found that MS patients with vascular co-morbidity at
diagnosis had more than a 1.5 folded increased risk of
ambulatory disability [7]. However, important differences
exist; we used another outcome measure and incorporated
co-morbid conditions occurring during follow-up.
Moreover, the methods for defining the co-morbid
disorders differed. We used four nationwide registers to
identify occurrences of co-morbidity, while Marrie et al.
[7] relied on self-reported data. Marrie et al used the
term vascular disorders, including e.g. diabetes, while we
employed ICD-10 chapters and pre-established groups of
ATC-codes when defining the co-morbid disorders.
That mental disorders are highly overrepresented among
MS patients has often been reported [18,19]. Several studies
have also shown that the severity of MS cannot be linked to
having depression or anxiety in a straight forward manner,
instead they are common in all forms and stages of MS,
[18,20-23] yet other studies have reported somewhat
contradictory findings [11,24]. However, the majority of
prior studies support the notion that the higher risk for DP
among MS patients with mental disorders cannot be
explained only as a consequence of especially high rates of
mental disorders among severe cases of MS. Still, when
interpreting the influence of mental disorders, some
caution is warranted as a common pathogenic agent
that influences inflammatory markers may be involved in
both MS and depression [25]. and MS may sometimes
cause mental disorders through purely psychological
mechanisms.
In contrast to mental disorders, co-morbidity of
musculoskeletal and cardiovascular disorders among
MS patients has seldom been studied. Previous attempts
to compare the presence of these disorders in an MS
population to that in a representative population without
MS have reported contradictory findings [26-28]. In
the present study, all results support the notion thatmusculoskeletal and cardiovascular disorders are more
common among individuals with MS than they are in
the general population.
The strengths of the present study is its population-based
and prospective cohort design, the large cohort covering a
whole country, no loss to follow up, i.e. avoiding selection
bias, and the use of several data sources to estimate the
prevalence of co-morbidities, i.e. information about
in-patient and outpatient specialized care, on specific
prescribed drugs, as well as on sick-leave diagnoses – rather
than self-reports. We know of no other study using such a
wide spectrum of data on co-morbidity.
A potential weakness with this study concerns the
potential influence of differential misclassification. First,
some drugs used to operationalize musculoskeletal and
mental disorders can also be prescribed for MS symptoms,
e.g. hypnotics and sedatives, centrally acting sympathomi-
metics, anesthetics, and muscle relaxants. Second, MS
patients consume more specialized health care and may
thereby be more likely to become diagnosed with an
additional disorder in this study. Third, it is possible
that MS patients are more likely to at some point before
receiving their MS diagnosis have been misdiagnosed with
a musculoskeletal or mental disorder. We thus recognize
that all used registers have their flaws that may both
underestimate and overestimate the true differences
between MS patients and the general population with re-
gard to prevalence rates of co-morbidities. To deal with
these limitations additional analyses, based on different case
ascription methods were conducted. On most occasions,
but not all, these analyses corroborated one another.Conclusions
To conclude; this study suggests that attention should
be given to co-morbidity in order to better understand
the DP trajectory among MS patients. This study was
based on fairly broad categories of disorders and it is
possible that different and/or more specific case ascrip-
tions would nuance our findings. Additional population-
based register studies focusing on how specific diagnoses
or drugs influence MS patients’ work incapacity would
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